BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27688186)

  • 1. Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors.
    Zhang C; Wang X; Liu H; Zhang M; Geng M; Sun L; Shen A; Zhang A
    Eur J Med Chem; 2017 Jan; 125():315-326. PubMed ID: 27688186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
    Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
    Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
    Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
    Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
    Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
    Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
    J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
    Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
    Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
    Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
    Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
    Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
    Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
    Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
    Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent.
    Mokale SN; Sakle NS; Bhavale SA; Lokwani DK; Shelke VR
    Anticancer Agents Med Chem; 2018; 18(7):1009-1015. PubMed ID: 29189180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
    Taddei M; Ferrini S; Giannotti L; Corsi M; Manetti F; Giannini G; Vesci L; Milazzo FM; Alloatti D; Guglielmi MB; Castorina M; Cervoni ML; Barbarino M; Foderà R; Carollo V; Pisano C; Armaroli S; Cabri W
    J Med Chem; 2014 Mar; 57(6):2258-74. PubMed ID: 24588105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
    Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
    Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis.
    Gümus M; Ozgur A; Tutar L; Disli A; Koca I; Tutar Y
    Curr Pharm Biotechnol; 2016; 17(14):1231-1245. PubMed ID: 27804852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.